Yew Bio-Pharm Group, Inc.
YEWB
Other OTC0.00
USD
+0.00
- -
CIK
0001548240
ISIN
US98584C1018
CUSIP
98584C101
Return %
Stock
S&P500
1Y
100.00
17.85
3Y
-99.80
64.56
5Y
-99.89
69.89
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Madam Guifang Qi
- Full Time Employees
- 35
- Sector
- Consumer Defensive
- Industry
- Agricultural Farm Products
- Address
- 9460 Telstar Avenue El Monte CA United States of America 91731
- IPO Date
- Nov 14, 2013
- CIK
- 0001548240
- Website
- yewbiopharm.com
- Similar Companies
- Business
- Yew Bio-Pharm Group, Inc. operates primarily as a cultivator, manufacturer, and seller of yew trees and related products, specializing in the production and sale of raw materials derived from yew trees used predominantly for traditional Chinese medicine (TCM) that contains Taxol, an anti-cancer compound. The company leverages a proprietary patented accelerated growth technology to cultivate yew trees rapidly, reducing the natural growth cycle from over 50 years to 2-3 years. Their product portfolio includes the cultivation and sale of yew tree branches and leaves, manufacturing of TCM products containing Taxol, organic food products, dietary supplements, and recently, personal care items such as yew-based shampoos, conditioners, and body wash. Yew Bio-Pharm operates mainly in China and has developed a B2C cross-border e-commerce platform targeting both the overseas Chinese community and global consumers, offering health products, daily necessities, beauty products, and accessories. Founded in 2007 and headquartered in El Monte, California, Yew Bio-Pharm Group has expanded its business segments to include TCM, yew tree cultivation, organic foods, dietary supplements, handicrafts, and cosmetics. The company holds significant permits from the Heilongjiang provincial government supporting the commercial sale of yew trees and yew-derived products, including Taxol-based TCM approved for secondary cancer treatment and other disorders by Chinese health authorities. In terms of recent developments, Yew Bio-Pharm Group established a wholly-owned cosmetic subsidiary in 2021 to launch personal care products such as yew shampoo, conditioner, and body wash, signifying a strategic expansion into the cosmetics industry. Additionally, the company has formed new joint planting contracts (e.g., Auricularia Auricula) and secured financial support to diversify its medicinal plant cultivation activities. The company continues to invest in expanding its e-commerce presence and organic product lines to tap into growing global health and wellness markets. Yew Bio-Pharm Group's operations encompass cultivation technologies, pharmaceutical-grade raw materials, traditional medicine manufacturing, cosmetic products, and dietary supplements. It serves pharmaceutical companies, healthcare providers, and retail consumers, with its core operations centered in China alongside worldwide distribution through online platforms. The company's unique accelerated growth method and government permits position it as a distinctive player in the sustainable production of yew-derived medicinal and consumer products. This comprehensive profile reflects Yew Bio-Pharm Group's strong foothold in the biotechnology and traditional medicine sectors, with recent strategic moves into cosmetics and e-commerce enhancing its market reach and product diversity.